Oncology Institute (DFPH) Receivables (2020 - 2026)

Oncology Institute (DFPH) has 7 years of Receivables data on file, last reported at $59.4 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables rose 19.7% year-over-year to $59.4 million; the trailing twelve-month figure through Mar 2026 stood at $59.4 million (up 19.7% YoY), and the FY2025 full-year result was $59.3 million, up 21.85% from the prior year.
• Receivables for Q1 2026 stood at $59.4 million, roughly flat from $59.3 million in the prior quarter.
• Across five years, Receivables topped out at $60.0 million in Q3 2025 and bottomed at $25.8 million in Q1 2022.
• The 5-year median for Receivables is $48.9 million (2023), against an average of $48.1 million.
• The widest annual swing landed in 2022, when Receivables surged 90.33%; it then retreated 16.0% in 2025.
• A 5-year view of Receivables shows it stood at $40.4 million in 2022, then advanced by 6.13% to $42.9 million in 2023, then rose by 13.45% to $48.7 million in 2024, then increased by 21.85% to $59.3 million in 2025, then gained by 0.22% to $59.4 million in 2026.
• The last three Receivables figures came in at $59.4 million (Q1 2026), $59.3 million (Q4 2025), and $60.0 million (Q3 2025), per Business Quant data.

Peer Comparison